Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology’s 74th Annual Scientific Session
Cardio Diagnostics Holdings (Nasdaq: CDIO) announced its participation in the American College of Cardiology's 74th Annual Scientific Session (ACC.25) in March 2025. The company will showcase its PrecisionCHD™ test and enhanced Actionable Clinical Intelligence (ACI™) report at Booth #2033.
PrecisionCHD™ is a prescription-based blood test that aids in diagnosing coronary heart disease (CHD) through analyzing 10 genetic and 6 epigenetic markers. The test requires no radiation or fasting and can be performed via standard blood draw or lancet sampling. The enhanced ACI™ report provides clearer insights into patients' modifiable disease drivers, including inflammation-related risk.
The company will present new research demonstrating PrecisionCHD™ methylation biomarkers' ability to predict mortality in Acute Coronary Syndrome (ACS) patients, showing superior predictive capabilities compared to traditional angiographic methods.
Cardio Diagnostics Holdings (Nasdaq: CDIO) ha annunciato la sua partecipazione alla 74ª Sessione Scientifica Annuale del Collegio Americano di Cardiologia (ACC.25) che si terrà a marzo 2025. L'azienda presenterà il suo test PrecisionCHD™ e il report migliorato di Intelligenza Clinica Azionabile (ACI™) presso lo Stand #2033.
PrecisionCHD™ è un test del sangue su prescrizione che aiuta a diagnosticare la malattia coronarica (CHD) analizzando 10 marcatori genetici e 6 epigenetici. Il test non richiede radiazioni né digiuno e può essere effettuato tramite prelievo di sangue standard o campionamento con lancetta. Il report ACI™ migliorato fornisce informazioni più chiare sui fattori modificabili della malattia nei pazienti, inclusi i rischi legati all'infiammazione.
L'azienda presenterà nuove ricerche che dimostrano la capacità dei biomarcatori di metilazione di PrecisionCHD™ di prevedere la mortalità nei pazienti con Sindrome Coronarica Acuta (ACS), mostrando capacità predittive superiori rispetto ai metodi angiografici tradizionali.
Cardio Diagnostics Holdings (Nasdaq: CDIO) anunció su participación en la 74ª Sesión Científica Anual del Colegio Americano de Cardiología (ACC.25) en marzo de 2025. La empresa exhibirá su prueba PrecisionCHD™ y el informe mejorado de Inteligencia Clínica Accionable (ACI™) en el Stand #2033.
PrecisionCHD™ es un análisis de sangre basado en receta que ayuda a diagnosticar la enfermedad coronaria (CHD) mediante el análisis de 10 marcadores genéticos y 6 epigenéticos. La prueba no requiere radiación ni ayuno y puede realizarse a través de un análisis de sangre estándar o muestreo con lanceta. El informe ACI™ mejorado proporciona una visión más clara sobre los factores modificables de la enfermedad en los pacientes, incluidos los riesgos relacionados con la inflamación.
La empresa presentará nueva investigación que demuestra la capacidad de los biomarcadores de metilación de PrecisionCHD™ para predecir la mortalidad en pacientes con Síndrome Coronario Agudo (ACS), mostrando capacidades predictivas superiores en comparación con los métodos angiográficos tradicionales.
Cardio Diagnostics Holdings (Nasdaq: CDIO)는 2025년 3월에 열리는 미국 심장학회 제74차 연례 과학 회의(ACC.25)에 참여한다고 발표했습니다. 이 회사는 부스 #2033에서 PrecisionCHD™ 테스트와 향상된 실행 가능한 임상 정보(ACI™) 보고서를 선보일 것입니다.
PrecisionCHD™는 10개의 유전 마커와 6개의 후천적 마커를 분석하여 관상 동맥 질환(CHD)을 진단하는 데 도움을 주는 처방 기반 혈액 검사입니다. 이 검사는 방사선이나 금식을 요구하지 않으며 표준 혈액 채취 또는 lancet 샘플링을 통해 수행될 수 있습니다. 향상된 ACI™ 보고서는 환자의 수정 가능한 질병 유발 요인, 특히 염증 관련 위험에 대한 더 명확한 통찰력을 제공합니다.
회사는 PrecisionCHD™ 메틸화 바이오마커가 급성 관상 동맥 증후군(ACS) 환자의 사망률을 예측할 수 있는 능력을 보여주는 새로운 연구를 발표할 예정이며, 이는 기존의 혈관조영술 방법에 비해 우수한 예측 능력을 보여줍니다.
Cardio Diagnostics Holdings (Nasdaq: CDIO) a annoncé sa participation à la 74e Session Scientifique Annuelle du Collège Américain de Cardiologie (ACC.25) qui se déroulera en mars 2025. L'entreprise présentera son test PrecisionCHD™ et le rapport amélioré Intelligence Clinique Actionnable (ACI™) au stand #2033.
PrecisionCHD™ est un test sanguin sur ordonnance qui aide à diagnostiquer la maladie coronarienne (CHD) en analysant 10 marqueurs génétiques et 6 marqueurs épigénétiques. Le test ne nécessite ni radiation ni jeûne et peut être effectué par une prise de sang standard ou un échantillonnage avec lancette. Le rapport ACI™ amélioré fournit des informations plus claires sur les facteurs modifiables de la maladie chez les patients, y compris les risques liés à l'inflammation.
L'entreprise présentera de nouvelles recherches démontrant la capacité des biomarqueurs de méthylation de PrecisionCHD™ à prédire la mortalité chez les patients atteints de syndrome coronarien aigu (ACS), montrant des capacités prédictives supérieures par rapport aux méthodes angiographiques traditionnelles.
Cardio Diagnostics Holdings (Nasdaq: CDIO) gab seine Teilnahme an der 74. Jahrestagung der American College of Cardiology (ACC.25) im März 2025 bekannt. Das Unternehmen wird seinen PrecisionCHD™ Test und den verbesserten Actionable Clinical Intelligence (ACI™) Bericht am Stand #2033 präsentieren.
PrecisionCHD™ ist ein verschreibungspflichtiger Bluttest, der bei der Diagnose von koronarer Herzkrankheit (CHD) hilft, indem er 10 genetische und 6 epigenetische Marker analysiert. Der Test erfordert keine Strahlung oder Fasten und kann durch eine Standard-Blutentnahme oder Lancettensampling durchgeführt werden. Der verbesserte ACI™ Bericht bietet klarere Einblicke in die veränderbaren Krankheitsfaktoren der Patienten, einschließlich entzündungsbezogener Risiken.
Das Unternehmen wird neue Forschungen präsentieren, die die Fähigkeit von PrecisionCHD™ Methylierungsbiomarkern demonstrieren, die Sterblichkeit bei Patienten mit akutem Koronarsyndrom (ACS) vorherzusagen, und dabei überlegene prädiktive Fähigkeiten im Vergleich zu traditionellen angiografischen Methoden zeigen.
- Development of enhanced diagnostic tool combining epigenetics, genetics, and AI for CHD detection
- Non-invasive blood test requiring no radiation or fasting
- Superior mortality prediction capabilities for ACS patients compared to traditional methods
- Integration potential with existing electronic health records systems
- Test only available by prescription, limiting direct consumer access
Cardio Diagnostics’ mission is to redefine cardiovascular care by combining epigenetics, genetics, and artificial intelligence to enable earlier detection of heart disease and more personalized patient management. Through our commitment to data-driven innovation, Cardio Diagnostics aims to prevent heart disease, improve diagnostic accuracy, and enable clinicians with actionable insights to deliver targeted, effective care.
Spotlight on PrecisionCHD™ and Actionable Clinical Intelligence (ACI™)
PrecisionCHD™, Cardio Diagnostics’ flagship solution, is a clinical blood test available by prescription to aid in the diagnosis and management of coronary heart disease (CHD). Unlike traditional diagnostic tools, PrecisionCHD™ is radiation-free, requires no fasting, and is performed through a simple blood draw, either via standard phlebotomy or lancet-based sampling. By evaluating a unique panel of 10 genetic and 6 epigenetic (DNA methylation) markers, PrecisionCHD™ provides clinicians with deep insights into the unique underlying molecular drivers of CHD for each patient.
Importantly, the test results map epigenetic biomarkers to modifiable risk factors, allowing clinicians to personalize patient management. For cardiologists, PrecisionCHD™ serves as a critical tool in the fight against CHD, offering a non-invasive, radiation-free method to assess molecular drivers of CHD that traditional diagnostics may overlook. With the ability to track changes over time, PrecisionCHD™ empowers cardiologists to refine treatment plans based on a patient’s unique epigenetic profile, ultimately driving more effective interventions and better long-term cardiovascular outcomes.
This year at ACC.25, Cardio Diagnostics will specifically highlight the updated Actionable Clinical Intelligence (ACI™) report for PrecisionCHD™, now enhanced to provide clearer, easier-to-interpret and more actionable clinical insights. The updated ACI™ leverages PrecisionCHD™’s six key methylation markers, giving prescribing clinicians sharper visibility into their patients’ modifiable drivers of disease, including inflammation-related risk - a critical advancement for personalized care.
“PrecisionCHD™ and our enhanced Actionable Clinical Intelligence™ deliver a level of insight that no other solution offers cardiologists today,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “By integrating epigenetics, genetics, and AI, we provide a clearer, more actionable understanding of a patient’s modifiable drivers of coronary heart disease. This empowers cardiologists to deliver truly personalized care and improve patient outcomes.”
Poster Presentation - Methylation Biomarkers as Predictors of Mortality in ACS Patients: A Critical Advancement for Clinical Cardiology
At ACC.25, Cardio Diagnostics will present compelling new data on the power of the methylation biomarkers of the PrecisionCHD™ test to predict mortality in patients with Acute Coronary Syndrome (ACS), offering cardiologists a novel, actionable tool to guide patient management to help improve survival outcomes.
The poster, titled “Synergistic Effects of Combining Methylation Data with Imaging Data in Predicting Mortality of Acute Coronary Syndrome (ACS) Patients,” highlights findings from a recent study by Cardio Diagnostics demonstrating the superiority of PrecisionCHD methylation indices to angiographic methods for predicting mortality risk in ACS patients. In addition, the study delineates a machine learning-based method that could be integrated within existing electronic health records systems to synergistically combine angiographic and methylation information for predicting mortality risk.
By interrogating key methylation pathways linked to inflammation and coronary heart disease, PrecisionCHD™ can enable clinicians to more effectively stratify mortality risk and personalize treatment plans for ACS patients, potentially improving outcomes.
“These findings underscore the power of methylation-based biomarkers in cardiovascular medicine,” said Rob Philibert, M.D., Ph.D., Chief Medical Officer of Cardio Diagnostics. “Traditional imaging tools provide valuable anatomical insights, but they fall short in predicting long-term mortality risk and providing mechanistic insights. Our study shows that methylation biomarkers not only fill this gap but also offer a more precise, biologically driven assessment of mortality risk, allowing cardiologists to intervene earlier and more effectively.”
Visit Cardio Diagnostics at Booth #2033
Attendees are invited to visit Booth #2033 to learn more about the Company’s PrecisionCHD™, Epi+Gen CHD™ and Actionable Clinical Intelligence™ solutions, and its broader vision for AI-driven, epigenetic-guided precision cardiovascular medicine. The Company’s executive team will also be onsite to engage with cardiologists, potential partners and attendees on how these innovations are transforming cardiovascular care.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/
Forward-Looking Statements
Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended in December 31, 2024, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326097652/en/
Investors:
Investor Relations
855-226-9991
investors@cdio.ai
Media & Public Relations
Public Relations
855-226-9991
pr@cdio.ai
Source: Cardio Diagnostics Holdings, Inc.
FAQ
What is PrecisionCHD™ test by CDIO and how does it work?
How does CDIO's enhanced Actionable Clinical Intelligence (ACI™) improve patient care?
What new research will CDIO present at ACC.25 regarding ACS patients?
When and where will CDIO showcase its cardiovascular solutions at ACC.25?
